C
Campbell D. Joyner
Researcher at Sunnybrook Health Sciences Centre
Publications - 47
Citations - 21365
Campbell D. Joyner is an academic researcher from Sunnybrook Health Sciences Centre. The author has contributed to research in topics: Stroke & Fondaparinux. The author has an hindex of 31, co-authored 47 publications receiving 19772 citations. Previous affiliations of Campbell D. Joyner include University of British Columbia & University of Toronto.
Papers
More filters
Journal ArticleDOI
Dabigatran versus warfarin in patients with atrial fibrillation
Stuart J. Connolly,Michael D. Ezekowitz,John W. Eikelboom,Jonas Oldgren,Amit Parekh,Janice Pogue,Paul A. Reilly,Ellison Themeles,Jeanne Varrone,Susan Wang,Marco Alings,Denis Xavier,Jun Zhu,Rafael Diaz,Basil S. Lewis,Harald Darius,Hans-Christoph Diener,Campbell D. Joyner,Lars Wallentin +18 more
TL;DR: In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage.
Journal ArticleDOI
Apixaban in Patients with Atrial Fibrillation
Stuart J. Connolly,John W. Eikelboom,Campbell D. Joyner,Hans-Christoph Diener,Robert G. Hart,Sergey P. Golitsyn,Greg C. Flaker,Alvaro Avezum,Stefan H. Hohnloser,Rafael Diaz,Mario Talajic,Jun Zhu,Prem Pais,Andrzej Budaj,Alexander Parkhomenko,Petr Jansky,Patrick J. Commerford,Ru San Tan,Kui-Hian Sim,Basil S. Lewis,Walter Van Mieghem,Jae Hyung Kim,Fernando Lanas-Zanetti,Antonio Gonzalez-Hermosillo,Antonio L. Dans,Muhammad Munawar,John H. Lawrence,Gayle Lewis,Rizwan Afzal,Salim Yusuf +29 more
TL;DR: In patients with atrial fibrillation for whom vitamin K antagonist therapy was unsuitable, apixaban reduced the risk of stroke or systemic embolism without significantly increasing therisk of major bleeding or intracranial hemorrhage.
Journal ArticleDOI
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial.
Sanjit S. Jolly,Salim Yusuf,John A. Cairns,Kari Niemelä,Denis Xavier,Petr Widimsky,Andrzej Budaj,Matti Niemelä,Vicent Valentin,Basil S. Lewis,Alvaro Avezum,Philippe Gabriel Steg,Sunil V. Rao,Peggy Gao,Rizwan Afzal,Campbell D. Joyner,Susan Chrolavicius,Shamir R. Mehta +17 more
TL;DR: The lower rate of local vascular complications may be a reason to use the radial approach in patients with acute coronary syndromes who were undergoing coronary angiography with possible intervention.
Journal ArticleDOI
Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
Salim Yusuf,Shamir R. Mehta,Susan Chrolavicius,Rizwan Afzal,Janice Pogue,Christopher B. Granger,Andrzej Budaj,Ron J.G. Peters,Jean-Pierre Bassand,Lars Wallentin,Campbell D. Joyner,Keith A.A. Fox +11 more
TL;DR: Fondaparinux is similar to enoxaparin in reducing the risk of ischemic events at nine days, but it substantially reduces major bleeding and improves long term mortality and morbidity.
Journal ArticleDOI
Canadian atrial fibrillation anticoaguiation (CAFA) study
Stuart J. Connolly,Andreas Laupacis,Michael Gent,Robin S. Roberts,John A. Cairns,Campbell D. Joyner +5 more
TL;DR: The Canadian Atrial Fibrillation Anticoagulation Study was a randomized double-blind placebo-controlled trial to assess the potential of warfarin to reduce systemic thromboembolism and its inherent risk of hemorrhage.